AFYA enters its August 26 Q2 print carrying the weight of a year-long analyst downgrade cycle — and a valuation that has cheapened enough to attract renewed attention.
The analyst story is the defining tension here. Every major firm covering AFYA has moved in the same direction over the past eight months: down. JP Morgan cut from Overweight to Neutral in January, BofA downgraded from Buy to Neutral in February, and Morgan Stanley moved to Underweight — all trimming targets in a cluster that reflects persistent concern about Brazil's regulatory environment for medical education and the drag from a weaker real. The most recent action came from JP Morgan in June, shaving its target to $21. Against AFYA's current price of $14.22, even the Underweight targets imply meaningful upside — which speaks to how far the stock has already fallen to meet the bears.
What makes this interesting is that the valuation has compressed to a level that bulls find hard to ignore. The trailing P/E now sits near 7.3x, with EV/EBITDA below 5x — multiples that screen cheaply even by Latin American edtech standards. The company ranks in the 97th percentile on EPS surprise, meaning it has a strong track record of beating estimates. The dividend yield adds another layer of support, ranking in the 95th percentile on dividend score. Bears counter that forward EPS momentum is deteriorating — the 30-day and 90-day momentum scores rank in the 29th and 20th percentiles respectively — suggesting estimate cuts may not be finished. That gap between a cheap stock on trailing multiples and weakening forward expectations is the core debate heading into the print.
Short interest barely registers as a driver. At under 1% of the free float, bears have not built a meaningful position. Borrow availability is comfortable at 173%, with cost to borrow running at just 0.66% — cheap and accessible for anyone wanting to add short exposure. The ORTEX short score has drifted higher recently, hitting 61 on August 21 after spending much of August in the high 50s to low 60s, but this reflects the broader cheapening of the stock rather than an aggressive tactical short build. Options positioning is mild — the put/call ratio of 0.57 is only modestly above its 20-day average of 0.51, with a z-score below one. Price action has been quietly constructive: AFYA gained 3% on the week even as it slipped 0.8% on Monday. The stock's education-sector peers broadly outperformed on the week, with COUR up nearly 9% and EDU up 6%, which makes AFYA's more muted recovery notable.
The print will test whether the company's persistent beat on EPS estimates can survive the deteriorating forward momentum picture — and whether management's commentary on Brazilian regulatory conditions and enrollment trends gives the upgraded Street any reason to revisit targets that still sit comfortably above where the stock is trading.
See the live data behind this article on ORTEX.
Open AFYA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
